MicroRNA‑376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma

Yao,Shuna; Liu,Yanyan; Yao,Zhihua; Zhao,Yan; Wang,Haiying; Xu,Yuanlin; Zhang,Jiuyang; Li,Jing; Yang,Shujun

doi:10.3892/ol.2018.9012

MicroRNA‑376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma

Authors:
- Shuna Yao
- Yanyan Liu
- Zhihua Yao
- Yan Zhao
- Haiying Wang
- Yuanlin Xu
- Jiuyang Zhang
- Jing Li
- Shujun Yang
View Affiliations

Affiliations: Section of Comprehensive Lymphoma, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, P.R. China
Published online on: June 22, 2018 https://doi.org/10.3892/ol.2018.9012
Pages: 3169-3176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate microRNA‑376a (miR‑376a) expression in lymphoma, and to investigate the effect of miR‑376a on cell proliferation and apoptosis at cytological and molecular levels. The expression of miR‑376a in lymphoma issue and cells was detected by reverse transcription quantitative polymerase chain reaction (RT‑qPCR), the expression of forkhead box protein P2 (FOXP2) was detected by RT‑qPCR and western blot analysis, and the effect of miR‑376a on cell proliferation and apoptosis were studied by an MTT assay and flow cytometry, respectively. Additionally, the expression levels of cyclin D2, cyclin A, cyclin B, apoptosis‑associated proteins B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑associated X protein (Bax) were detected by western blot analysis. Furthermore, the target of miR‑376a was predicted and clarified using a dual‑luciferase reporter assay. The expression of miR‑376a was downregulated and FOXP2 was upregulated in lymphoma tissues and cells. miR‑376a overexpression inhibited lymphoma cell proliferation and induced apoptosis by regulating the expression levels of cyclin D2, cyclin A, Bax and Bcl‑2. The dual‑luciferase reporter assay demonstrated that FOXP2 was a target of miR‑376a. miR‑376a overexpression induced apoptosis by targeting FOXP2. Overexpression of miR‑376a inhibited cell proliferation and induced apoptosis by targeting FOXP2 in lymphoma. Therefore, miR‑376a and FOXP2 have the potential for use as biomarkers of lymphoma.

View Figures

View References

1	Scott DW and Gascoyne RD: The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 14:517–534. 2014. View Article : Google Scholar : PubMed/NCBI
2	Marcus EBR, Sweetenham JW and Williams ME: Pathology, diagnosis and treatment. Cambridge University Press; 2013, View Article : Google Scholar
3	Kuna T, John O, Kobler P and Filipovićzore I: A finding of diffuse cellular non-Hodgkin lymphoma in the oral cavity-case presentation Dg: Diffuse giant cell Non-Hodgkin lymphoma B-immunophenotype. Acta Stomatol Croatica. 38:2792004.
4	Bardia A and Seifter E: Johns Hopkins Patients' Guide to Lymphoma. Shockney L and Shapiro GR: Jones and Bartlett; Sudbury, MA, USA: 2011
5	Armitage JO, Gascoyne RD, Lunning MA and Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017. View Article : Google Scholar : PubMed/NCBI
6	Surveillance E and Program ER: SEER stat fact sheets: Non-Hodgkin Lymphoma. 2014.
7	Stewart BW and Wild CP: World Cancer Report 2014. IARC Publications; Lyon, France: 2015
8	Paydas S, Acikalin A, Ergin M, Celik H, Yavuz B and Tanriverdi K: Micro-RNA (miRNA) profile in Hodgkin lymphoma: Association between clinical and pathological variables. Med Oncol. 33:342016. View Article : Google Scholar : PubMed/NCBI
9	Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R and Kerin MJ: Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 131:2215–2222. 2012. View Article : Google Scholar : PubMed/NCBI
10	Musilova K and Mraz M: MicroRNAs in B-cell lymphomas: How a complex biology gets more complex. Leukemia. 29:1004–1017. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zheng Y, Yin L, Chen H, Yang S, Pan C, Lu S, Miao M and Jiao B: miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett. 586:2396–2403. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Avni D and Leibowitz-Amit R: Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: Biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer. 11:442012. View Article : Google Scholar : PubMed/NCBI
13	Arribas AJ, Gómez-Abad C, Sánchez-Beato M, Martinez N, Dilisio L, Casado F, Cruz MA, Algara P, Piris MA and Mollejo M: Splenic marginal zone lymphoma: Comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 26:889–901. 2013. View Article : Google Scholar : PubMed/NCBI
14	Yu X, Li Z and Liu J: MiRNAs in primary cutaneous lymphomas. Cell Prolif. 48:271–277. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lawrie CH: MicroRNAs and lymphomagenesis: A functional review. Br J Haematol. 160:571–581. 2013. View Article : Google Scholar : PubMed/NCBI
16	Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, et al: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 384:470–474. 1996. View Article : Google Scholar : PubMed/NCBI
19	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM and Sen S: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2:807–813. 2009. View Article : Google Scholar : PubMed/NCBI
21	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Ann Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
23	Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A and Cascante M: Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
24	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
25	Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
26	Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 147:545–560. 1995.PubMed/NCBI
27	Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
28	Bartkova J, Lukas J, Strauss M and Bartek J: The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer. 58:568–573. 1994. View Article : Google Scholar : PubMed/NCBI
29	Motokura T and Arnold A: Cyclins and oncogenesis. Biochim Biophys Acta. 1155:63–78. 1993.PubMed/NCBI
30	Surhone LM, Tennoe MT, Henssonow SF, Macromolecule and Acid N: Cyclin D2. 2011.
31	Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
32	Fuchs Y and Steller H: Programmed cell death in animal development and disease. Cell. 147:742–758. 2011. View Article : Google Scholar : PubMed/NCBI
33	Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
34	Tsui D, Vessey JP, Tomita H, Kaplan DR and Miller FD: FoxP2 regulates neurogenesis during embryonic cortical development. J Neurosci. 33:244–258. 2013. View Article : Google Scholar : PubMed/NCBI
35	Vernes SC, Oliver PL, Spiteri E, Lockstone HE, Puliyadi R, Taylor JM, Ho J, Mombereau C, Brewer A, Lowy E, et al: Foxp2 regulates gene networks implicated in neurite outgrowth in the developing brain. PLoS Genetics. 7:e10021452011. View Article : Google Scholar : PubMed/NCBI
36	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
37	Bignone PA and Banham AH: FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther. 8:1897–1920. 2008. View Article : Google Scholar : PubMed/NCBI
38	Teufel A, Wong EA, Mukhopadhyay M, Malik N and Westphal H: FoxP4, a novel forkhead transcription factor. Biochim Biophys Acta. 1627:147–152. 2003. View Article : Google Scholar : PubMed/NCBI
39	Campbell AJ, Lyne L, Brown PJ, Launchbury RJ, Bignone P, Chi J, Roncador G, Lawrie CH, Gatter KC, Kusec R and Banham AH: Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. Br J Haematol. 149:221–230. 2010. View Article : Google Scholar : PubMed/NCBI